Form 4: Sutro Biopharma Director Granted Stock Options
Insider Transaction Report
Sutro Biopharma director Daniel H. Petree was granted 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.
Summary
- Daniel H. Petree, a Director of Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
- The transaction date for this grant was December 23, 2025.
- Each option has an exercise price of $10.38.
- The options will vest as to 16.67% of the total award monthly, subject to continued service.
- The first tranche of options is scheduled to vest on January 23, 2026.
- The options have an expiration date of December 23, 2035.
- Following this transaction, Daniel H. Petree beneficially owns 1,500 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as it represents a routine compensation event that aligns director interests with the company's performance, without indicating any immediate negative implications.
Positives
- The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
- The vesting schedule encourages continued service and commitment from the director.
Future Outlook
The stock options granted to Daniel H. Petree are subject to a monthly vesting schedule, with the first tranche vesting on January 23, 2026, and continuing thereafter, contingent on his continued service to the company.
Management Comments
- "The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026."
Industry Context
Equity grants, such as stock options, are a common component of executive and director compensation packages in the biopharmaceutical industry, designed to attract and retain talent while aligning their financial interests with long-term shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | Daniel H. Petree executed a Limited Power of Attorney, appointing Regina Cheng, David Pauling, and Gregory Chow as attorneys-in-fact to execute and file Forms 3, 4, and 5 on his behalf with the SEC. | October 6, 2025 | This streamlines the process for timely and compliant reporting of insider transactions for the director, enhancing administrative efficiency in corporate governance. |
Stakeholder Impact
- Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved long-term value creation.
Next Steps
- The stock options will begin vesting on January 23, 2026, with subsequent tranches vesting monthly thereafter.
Key Dates
| Date | Description |
|---|---|
| October 6, 2025 | Date Limited Power of Attorney was executed by Daniel H. Petree. |
| December 23, 2025 | Date of stock option grant to Daniel H. Petree. |
| January 23, 2026 | First tranche vesting date for the granted stock options. |
| December 23, 2035 | Expiration date of the granted stock options. |
Keywords
Sutro Biopharma, STRO, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.